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Ewing sarcoma cells depend on the EWS-FLI1 fusion
transcription factor for cell survival. Using an assay
of EWS-FLI1 activity and genome-wide RNAi
screening, we have identified proteins required for
the processing of the EWS-FLI1 pre-mRNA. We
show that Ewing sarcoma cells harboring a genomic
breakpoint that retains exon 8 of EWSR1 require the
RNA-binding protein HNRNPH1 to express in-frame
EWS-FLI1. We also demonstrate the sensitivity of
EWS-FLI1 fusion transcripts to the loss of function
of the U2 snRNP component, SF3B1. Disrupted
splicing of the EWS-FLI1 transcript alters EWS-FLI1
protein expression and EWS-FLI1-driven expres-
sion. Our results show that the processing of the
EWS-FLI1 fusion RNA is a potentially targetable
vulnerability in Ewing sarcoma cells.INTRODUCTION
Chromosomal translocations that generate fusion genes encod-
ing oncogenic transcription factors are associated with the initi-
ation and maintenance of many cancers, including leukemias
and epithelial and mesenchymal solid tumors (Mitelman et al.,
2007). Ewing sarcoma (ES) is an aggressive cancer of the bone598 Cell Reports 14, 598–610, January 26, 2016 ª2016 The Authorsand soft tissue (Hawkins et al., 2011). The primary oncogenic
event in 85% of ES tumors is a t(11:22)(q24:q12) translocation
(Delattre et al., 1992). This translocation generates a fusion gene
containing the 50 end of the EWSR1 gene and the 30 end of the
FLI1 gene, referred to as EWS-FLI1 (Delattre et al., 1992; May
et al., 1993a). The EWS-FLI1 transcript encodes the transcription
factor EWS-FLI1, which is responsible for malignant transforma-
tion and is necessary for ES cell survival (Bailly et al., 1994; May
et al., 1993a, 1993b). Molecules that either suppress the expres-
sion or inhibit the activity of an oncogenic transcription factor
have the potential to block cancer cell growth selectively. In
this study, we used a genome-wide RNAi screen of a cell-based
reporter assay to identify proteins required for EWS-FLI1 activity.
This screening strategy revealed the sensitivity of ES cells to the
reduced expression of proteins required for the processing and
maturation of the EWS-FLI1 fusion transcript.
The genomic breakpoints within the EWSR1 and FLI1 genes
that give rise to the expression of EWS-FLI1 vary (Zucman
et al., 1992, 1993; Zucman-Rossi et al., 1998). The breakpoint
cluster region (BCR) in EWSR1 is small (5 kb) but spans several
exons (exons 7–11). The BCR in FLI1 is much larger (over 30 kb),
extending from exons 4–9. The EWS-FLI1 transcript observed
most frequently consists of a fusion of exons 1–7 of EWSR1 to
exons 6–9 of FLI1, referred to as a 7/6 or type 1 fusion. Another,
rarer, EWS-FLI1 transcript consists of the fusion of EWSR1
exons 1–7 to FLI1 exons 5–9, referred to as a 7/5 or type 2 fusion.
The breakpoints observed in ES tumors occur typically within in-
trons of EWSR1 or FLI1, and expression of EWS-FLI1 requires
Figure 1. Identification of Proteins Required
for EWS-FLI1 Activity by Genome-wide RNAi
Screening
(A) A genome-wide RNAi screen of EWS-FLI1 ac-
tivity. Data are shown as the median Z for the three
siRNAs corresponding to each gene (21,000
genes) except for POL2RA (light blue circles),
EWSR1 (magenta diamonds), and FLI1 (dark blue
squares) for which the Z of each of the three
siRNAs targeting each gene are shown.
(B) The Zdiff (ZNR0B1  ZCMV) for the EWSR1 and
FLI1 siRNAs included in the screen and a sche-
matic of the sites in EWSR1, FLI1, and, EWS-FLI1
targeted by these siRNAs.
(C) The median Zdiff (ZNR0B1  ZCMV) (three siRNAs
per gene) for the 139 genes, selected for follow-up
analysis, that exhibited a selective decrease in the
TC32-NR0B1-luc reporter when silenced.
(D) Ratio of the TC32-NR0B1-luc and TC32-CMV-
luc reporter signals, 72 hr post-siRNA transfection
(mean ± SD, n = 5). **p < 0.01; ***p < 0.001,
compared to siNeg.
See also Figure S1 and Table S1.the splicing machinery to generate an in-frame transcript. Spe-
cifically, translocations that retain exon 8 of EWSR1 generate
an out-of-frame transcript unless this exon is removed (Berger
et al., 2013; Crompton et al., 2014; Pato´cs et al., 2013; Zoubek
et al., 1994; Zucman et al., 1993). A recent study showed that
15 of 42 ES tumors harbored translocations in which the
EWSR1 exon 8 must be spliced out to express an in-frame
EWS-FLI1 transcript (Berger et al., 2013). Here, we demonstrate
that the heterogeneous nuclear ribonucleoprotein H1
(HNRNPH1) is required for the splicing of EWS-FLI1 transcripts
expressed in ES cells in which the breakpoint retains EWSR1
exon 8. We also show that ES cell lines harboring 7/6 or 7/5
EWS-FLI1 fusions are sensitive to the inhibition of the core
splicing factor, SF3B1. This study establishes splicing as a
vulnerability that could be exploited for the development of ther-
apeutic strategies for ES.
RESULTS
RNA Processing Proteins Required for EWS-FLI1
Activity Are Identified by Genome-wide RNAi Screening
Parallel genome-wide RNAi screens were conducted in TC32 ES
cells expressing a luciferase reporter protein driven by either theCell Reports 14, 598–610promoter of the EWS-FLI1 regulated gene
NR0B1 (TC32-NR0B1-luc) or the CMV
promoter (TC32-CMV-luc) (Grohar et al.,
2011) (Figure S1A). Luciferase activity
was assessed 48 hr post-siRNA (small
interfering RNA) transfection. Assay opti-
mization and screen quality control data
are presented in Figures S1B–S1D.
Genome-wide TC32-NR0B1-luc and
TC32-CMV-luc RNAi screening data
were normalized and Z score transformed
(Chung et al., 2008). Next, the microRNA(miRNA)-like seed sequence of each siRNA was determined
and used to generate an adjusted Z score value (Z) (Buehler
et al., 2012). Comparison of the Zs for each siRNA in each screen
distinguished siRNAs affecting transcription in a non-specific
manner (e.g., POLR2A) from those siRNAs that target the
EWS-FLI1 fusion transcript directly (Figures 1A and 1B). To prior-
itize genes for confirmation, we focused on genes for which the
median seed-adjusted Zdiff (ZNR0B1  ZCMV) for the three siRNAs
per gene was either less than1.5 (the top 1% of candidates) or
more than 2 (the top 0.25% of candidates). We selected 183
genes (plus EWSR1 and FLI1) for a confirmatory screen: 137
genes that, when silenced, selectively reduced the TC32-
NR0B1-luc signal (group 1) (Figure 1C) and 46 genes that selec-
tively increased the TC32-NR0B1-luc signal (group 2) (Fig-
ure S1E) relative to the TC32-CMV-luc signal. In most cases,
an additional four siRNAs per gene were tested (Table S1).
We defined a gene as a priority candidate if at least two
further siRNAs mediated a Zdiff less than 1.5 for group 1 genes
or a Zdiff greater than 1.5 for group 2 genes in the reporter assay.
Based on these criteria, 26 group 1 genes and 16 group 2 genes
were supported by two or more siRNAs. The top gene ontology
terms associated with the 26 group 1 genes were mRNA splicing
(p value [Bonferroni corrected] = 1.4208) and mRNA processing, January 26, 2016 ª2016 The Authors 599
Figure 2. EWS-FLI1 Driven Expression in
TC32 Cells Is Altered by the Silencing of
SF3B1, SUPT6H, or HNRNPH1
(A) GSEA of the transcriptome of SF3B1-,
SUPT6H-, or HNRNPH1-silenced TC32 cells
(48 hr) using a set of genes upregulated (751) or
downregulated (494) in ES.
(B) Heatmap representation of the fold change
(Log2) in the expression of genes deregulated in ES
following silencing of SF3B1, SUPT6H, or
HNRNPH1 in TC32 cells (48 hr).
(C) qPCR assessment of EWS-FLI1 expression in
HNRNPH1-, SF3B1-, or SUPT6H-silenced TC32
cells (48 hr). Data are expressed relative to siNeg-
transfected cells (mean ± SD, n = 3).
(D) Immunoblot analysis of whole-cell lysates
prepared from ES cells 48 hr post-transfection of
HNRNPH1, SF3B1, or SUPT6H siRNAs using an-
tibodies against the proteins indicated.
(E) Relative viability of TC32 cells 48 and 72 hr
post-siRNA transfection (siNeg median normal-
ized, mean ± SD, n = 5).
*p < 0.05; **p < 0.01; ***p < 0.001, compared to
siNeg.
See also Figure S2 and Tables S2 and S3.(p value [Bonferroni corrected] = 2.3207). RNA-processing
genes identified included SF3B1, SF3A1, SNRPD1, and
SNRPD2, which encode components of the U2 small nuclear
ribonucleoprotein particle (snRNP). The transcription elongation
factor and histone chaperone SUPT6H and a non-core alterna-
tive splicing factor, the heterogeneous nuclear ribonucleoprotein
HNRNPH1, were also identified as required for EWS-FLI1 activ-
ity. Further analysis of the effects of silencing SF3B1, SUPT6H,
or HNRNPH1 in the TC32 reporter assay (six siRNAs per gene;
see Supplemental Experimental Procedures) confirmed that
the depletion of these proteins induces a selective decrease in
the NR0B1-luc reporter (Figure 1D).
EWS-FLI1 Driven Expression Is Altered by the Silencing
of SF3B1, SUPT6H, or HNRNPH1
To investigate the mechanistic basis for the identification of
SF3B1, SUPT6H, or HNRNPH1 as required for the activity of
EWS-FLI1, we confirmed their silencing by multiple siRNAs (Fig-600 Cell Reports 14, 598–610, January 26, 2016 ª2016 The Authorsure S2A) and then selected three siRNAs
per gene to generate expression profiles
of silenced TC32 cells (Figures S2B–
S2D). To determine whether silencing
SF3B1, SUPT6H, or HNRNPH1 results in
specific changes in expression of genes
that are deregulated in ES, or a broad,
pleiotropic effect because of their impor-
tance in the processing of RNA, we con-
ducted gene set enrichment analysis
(GSEA) using a set of genes previously
shown to exhibit altered expression in
ES (Figure 2A). For this analysis, we
used a list of 1,200 genes assembled
using multiple datasets that encompassboth genes regulated by EWS-FLI1 directly and indirectly (Table
S2) (Hancock and Lessnick, 2008; Kauer et al., 2009). The tran-
scriptome of SF3B1-silenced TC32 cells showed no enrichment
for alterations in the expression of genes specifically deregulated
in ES (Figure 2A, upper panels). In contrast, the transcriptome of
HNRNPH1-silenced TC32 cells was highly enriched for the
downregulation of genes overexpressed in ES and upregulation
of repressed genes (family-wise error rate [FWER] p < 0.001 for
all analyses performed) (Figure 2A, lower panels). These findings
were confirmed using additional datasets of EWS-FLI1-regu-
lated genes (Bilke et al., 2013; Riggi et al., 2014) (Figure S2E).
The transcriptome of SUPT6H-silenced TC32 cells also indi-
cated reversal in the expression of genes exhibiting altered
expression in ES (Figure 2A, middle panels).
Next, we focused on those genes that exhibited differential
expression in HNRNPH1-, SUPT6H-, or SF3B1-silenced TC32
cells. In total, 2,840 genes were considered differentially ex-
pressed (fold change greater than ±1.5, false discovery rate
[FDR] < 0.05, two or more siRNAs per gene; Figure S2F; Table
S3), of which 652 exhibited altered expression following
silencing of two or more genes (Figure S2G). To identify genes
related to ES biology within the set of 2,840 differentially ex-
pressed genes, we overlapped our data with the results of a
study detailing genes deregulated in ES (Kauer et al., 2009) (Fig-
ure 2B). This analysis demonstrated reversal of the expression of
many genes deregulated by EWS-FLI1, including decreased
expression of NR0B1 in SUPT6H- or HNRNPH1-silenced TC32
cells (Figure S2D). Importantly, though the transcriptome of
SF3B1-silenced TC32 cells showed no enrichment for the
altered expression of ES-specific genes or decreased expres-
sion of NR0B1, several genes recently reported as activated by
EWS-FLI1 (Riggi et al., 2014) were downregulated following
silencing of SF3B1 (Figure S2H). Overall, these data suggest
that the silencing of SF3B1, SUPT6H, or HNRNPH1 results in
some selective changes in the expression of genes that are de-
regulated in ES. Next, we assessed whether each protein is
required for the expression of the EWS-FLI1 fusion transcript it-
self, using qPCR primers spanning the fusion breakpoint
(EWSR1 exon 7/FLI1 exon 7; E7/F7). Depletion of SF3B1 medi-
ated a 5.5-fold decrease in EWS-FLI1 expression, while deple-
tion of HNRNPH1 resulted in a 3.75-fold decrease and depletion
of SUPT6H resulted in a 1.9-fold decrease (Figure 2C).
Analysis of EWS-FLI1 protein (Figure 2D) showed that
silencing of HNRNPH1 in TC32 cells mediated an almost com-
plete elimination of oncoprotein expression. Silencing of
SUPT6H also decreased EWS-FLI1 protein levels, but to a lesser
extent. Interestingly, while qPCR detected a decrease in EWS-
FLI1 RNA levels following silencing of SF3B1, immunoblot
analysis of EWS-FLI1 detected multiple products, leading us to
speculate that silencing of SF3B1 results in expression of
EWS-FLI1 transcript variants undetected by the E7/F7 primers.
Overall, these observations are consistent with the reduced
expression of SF3B1, SUPT6H, or HNRNPH1 leading to altered
expression of the EWS-FLI1 mRNA, the EWS-FLI1 protein, and,
thus, its activity. ES cells depend on the activity of EWS-FLI1 for
survival, and so disruption of the maturation of the EWS-FLI1
transcript should result in a reduction in viability of ES cells.
This was borne out by analysis of SF3B1-, SUPT6H-, or
HNRNPH1-silenced TC32 cells that exhibited a similar reduction
in viability as EWS-FLI1-silenced cells (Figure 2E).
HNRNPH1 Is Required for the Splicing of EWS-FLI1 in ES
Cell Lines with a Genomic Breakpoint that Retain
EWSR1 Exon 8
The chromosome 22 translocation breakpoint in the TC32 cell
line is within intron 8 of EWSR1 (May et al., 1993a). Thus, to
generate an in-frame EWS-FLI1 transcript, exon 8 of EWSR1
must be excised by splicing (Berger et al., 2013; May et al.,
1993a). To determine whether the role of HNRNPH1, SF3B1,
and SUPT6H in the maturation of the EWS-FL11 transcript
applied to just TC32 cells or whether these proteins are required
for the processing of the EWS-FLI1 transcript more broadly, we
silenced each gene in additional ES lines representing different
ES translocations and transcript types (Figure 3A).
EWS-FLI1 expression was reduced in all four ES cell lines
following silencing of SF3B1 (Figure 3B) and, to a lesser extent,Cfollowing silencing of SUPT6H (Figure S3A). In contrast,
silencing of HNRNPH1 in SKNMC cells mediated a decrease
in the expression of EWS-FLI1, similar to TC32 cells but
induced minimal changes in EWS-FLI1 expression in the other
ES cell lines (Figure 3C). SKNMC cells harbor a similar chromo-
some 22 translocation as TC32 cells, and so these results imply
that HNRNPH1 is specifically required for the processing of
EWS-FLI1 pre-mRNAs containing EWSR1 exon 8, while all ES
cells require SF3B1 and SUPT6H to process EWS-FLI1.
Because of their defined roles in splicing, we focused our sub-
sequent studies on HNRNPH1 and SF3B1, beginning with anal-
ysis of the putative function of HNRNPH1 in the splicing of
EWSR1 exon 8 to generate an in-frame EWS-FLI1 transcript
in ES cells with a chromosome 22 translocation downstream
of this exon.
To determine whether HNRNPH1 is required for the splicing
of EWSR1 exon 8 from the EWS-FLI1 pre-mRNA expressed in
TC32 or SKNMC ES cells, we performed an analysis using an
EWSR1 exon 6 forward and FLI1 exon 6 reverse primer pair
(E6/F6). Analysis of siNeg-transfected cells generated a single
PCR product of the predicted size (Figure 3D) and sequence
at the fusion breakpoint (Figure S3B). We also detected a sin-
gle PCR product following silencing of HNRNPH1 in TC71 or
RD-ES cells (Figure 3D). In contrast, silencing of HNRNPH1
in TC32 and SKNMC cells resulted in the detection of an addi-
tional PCR product of the size expected if exon 8 of EWSR1 is
retained (a and b in Figure 3D). Retention of EWSR1 exon 8
was confirmed by sequencing. The failure to exclude
EWSR1 exon 8 is predicted to result in the generation of an
out-of-frame transcript (Figure S3C) that does not encode
the EWS-FLI1 oncoprotein (Figure 3E). This finding explains
the altered expression of EWS-FLI1-regulated genes
observed following whole-transcriptome analysis of
HNRNPH1-silenced TC32 cells (Figures 2A and 2B) and the
identification of this protein as required for EWS-FLI1 activity
by the RNAi screen.
The Silencing of HNRNPH1 Reverses the Expression of
Genes Deregulated by EWS-FLI1
To confirm the selective effect of the silencing of HNRNPH1 on
the expression of EWS-FLI1-regulated genes in ES cells with a
chromosome 22 translocation within EWSR1 intron 8, we exam-
ined the expression of 12 genes regulated by EWS-FLI1 (see
Supplemental Experimental Procedures). All 12 genes exhibited
significant changes in expression in HNRNPH1-silenced
SKNMC cells (Figure 4A, upper panel). Critically, we observed
no changes in the expression of the same genes when
HNRNPH1 was silenced in TC71 cells (Figure 4A, lower panel).
The selective effect of silencing of HNRNPH1 on EWS-FLI1
expression—and, thus, its activity—in TC32 and SKNMC cells
was further validated when we examined EZH2, PRKCB, and
VRK1 protein expression in these cell lines following silencing
of HNRNPH1 versus HNRNPH1-silenced TC71 or RD-ES cells
(Figure 4B). Importantly, the silencing ofHNRNPH1 in TC32 cells
resulted in a highly significant decrease in cell viability, similar to
the direct silencing of EWS-FLI1, while the silencing of
HNRNPH1 in TC71 resulted in minimal changes in cell viability
(Figure 4C).ell Reports 14, 598–610, January 26, 2016 ª2016 The Authors 601
Figure 3. HNRNPH1 Is Required for the
Splicing of EWS-FLI1 in ES Cell Lines with
a Genomic Breakpoint that Retains EWSR1
Exon 8
(A) Schematic of the organization of the EWSR1
and FLI1 genes and EWS-FLI1 fusion transcripts in
ES cell lines. EWSR1 exons are indicated in
magenta, and FLI1 exons are indicated in blue. The
EWSR1 and FLI1 exon counts are based on
NM_05243 and NM_002017 reference sequences.
(B) Expression of SF3B1 and EWS-FLI1 (E7/F7
primer pair) in SF3B1-silenced ES cells (48 hr).
Data are expressed relative to siNeg-transfected
cells (mean ± SD, n = 3).
(C) Expression of HNRNPH1 and EWS-FLI1 (E7/F7
primer pair) in HNRNPH1-silenced ES cells (48 hr).
Data are expressed relative to siNeg-transfected
cells (mean ± SD, n = 3).
(D) PCR analysis of the splicing of EWS-FLI1 using
E6/F6 primer pair and sequence analysis of the
amplified products labeled a and b focusing on the
junction of EWSR1 exons 7 and 8 and EWSR1
exon 8 and FLI1 exon 7.
(E) Immunoblot analysis of whole-cell lysates pre-
pared from TC32 cells 48 hr post-siRNA trans-
fection using antibodies against the proteins
indicated.
*p < 0.05; **p < 0.01; ***p < 0.001, compared to
siNeg.
See also Figure S3.HNRNPH1 Binds the EWS-FLI1 Pre-mRNA Expressed in
TC32 and SKNMC Ewing Sarcoma Cells
Next, we used an RNA pull-down strategy to determine
whether HNRNPH1 binds the EWS-FLI1 pre-mRNA expressed
in TC32 cells directly (Figure S4A). In the nuclear fraction,
we observed enrichment of EWS-FLI1 pre-mRNA in
HNRNPH1 pull-down samples over the immunoglobulin G
(IgG) pull-down control at EWSR1 exons 5 and 8 (Figure 4D).
There was no enrichment of EWS-FLI1 RNA in the cytosol
fraction (Figure S4B). The results of the RNA pull-down
prompted us to next examine EWSR1 exon 8 for potential
HNRNPH1 binding sites. The EWSR1 exon 8 sequence
indicated two G-rich sequences consistent with the reported
binding-motif of HNRNPH1 (Huelga et al., 2012) (Figure 4E).
An in vitro protein-RNA-oligomer binding assay (Figure S4C)
confirmed that HNRNPH1 is able to bind to either of these
sequences (Figure 4F). These results demonstrate a
sequence-specific, breakpoint-dependent vulnerability in ES
cells.602 Cell Reports 14, 598–610, January 26, 2016 ª2016 The AuthorsPhysiological Levels of SF3B1 Are
Required for Expression of
EWS-FLI1
A decrease in EWS-FLI1 mRNA levels
was observed in SF3B1-silenced ES
cell lines representing different break-
points and fusion types (Figure 3B).
However, the presence of multiple
variant proteins in SF3B1-depleted ES
cells (Figure 5A) suggests that the ef-fects of SF3B1 silencing on the splicing of the fusion transcript
are complex. One possibility is that SF3B1 silencing results in
both reduced expression of full-length EWS-FLI1 and the
expression of mis-spliced EWS-FLI1 variant transcripts that
are in frame. To test this hypothesis, we performed a PCR
analysis of RNA from siRNA-transfected SKNMC cells using
the E7/F7 primer pair and a second primer pair consisting of
the same forward primer but with a FLI1 exon 9 reverse
primer (E7/F9) (Figure 5B). As expected, we observed a sub-
stantial decrease in EWS-FLI1 expression in HNRNPH1-
silenced SKMNC cells using either PCR primer pair. The
E7/F7 primer pair detected a similar reduction in EWS-FLI1
expression in SF3B1-silenced SKNMC cells, but the E7/F9
primer pair detected only a partial loss of EWS-FLI1 expres-
sion, indicating the expression of a variant EWS-FLI1 transcript
that excludes FLI1 exon 7 but includes FLI1 exon 9. These re-
sults suggest that physiological levels of SF3B1 are required
for the generation of an EWS-FLI1 transcript that includes all
exons and that disruption of spliceosome activity can result
Figure 4. HNRNPH1 Directly Binds the EWS-FLI1 Pre-mRNA Expressed in TC32 Cells
(A) Expression of EWS-FLI1-regulated genes inHNRNPH1-silenced SKNMC or TC71 cells. Data are expressed relative to untransfected cells (mean ± SD, n = 3).
*p < 0.05; **p < 0.01; ***p < 0.001, compared to siNeg.
(B) Immunoblot analysis of whole-cell lysates prepared from ES cells 48 hr post-siRNA transfection using antibodies against the proteins indicated.
(C) The viability of TC32 and TC71 cells 72 hr post-siRNA transfection (siNeg median normalized, mean ± SD, n = 10). The p values are compared to siNeg.
(D) UV-crosslinked RNA from TC32 cells (nuclear fraction) were subjected to RNA immunoprecipitation using an HNRNPH1 antibody or a control IgG isotype
control. The fold enrichment of co-precipitating RNA (HNRNPH1 bound versus IgG control) was determined by qPCR across regions of the EWS-FLI1 transcript
(see Figure S4A). Data are shown as the mean ± SEM of three experiments.
(E) Sequence of EWSR1 exon 8 indicating putative G-rich HNRNPH1 binding sites.
(legend continued on next page)
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in the generation of variant EWS-FLI1 transcripts with altered
exon usage.
Exons Adjacent and Downstream of the Fusion in EWS-
FLI1 Are Vulnerable to Disruption of Spliceosome
Activity
To determine whether depletion of SF3B1 results in altered
splicing of EWS-FLI1, we conducted a PCR analysis of the exons
closest to the breakpoint (Figure 5C). Using an EWSR1 exon
7-FLI1 exon 8 PCR primer pair (E7/F8) and cDNA generated
from siNeg-transfected cells, we amplified single products of
the expected sizes. In contrast, analysis of RNA from SF3B1-
silenced cells (TC32, SKNMC, TC71, and RD-ES) showed the
presence of multiple PCR products. The sizes of these PCR
products were consistent with mis-splicing of exons close to
and downstream from the fusion breakpoint, regardless of fusion
type. Sequencing of PCRproducts derived fromSF3B1-silenced
TC32 or SKNMC cells showed the splicing of EWSR1 exon 8 to
FLI1 exon 8 (labels a and c in Figure 5C). This product is out of
frame and establishes that TC32 and SKNMC cells also require
SF3B1 to exclude EWSR1 exon 8 from EWS-FLI1, a finding
confirmed using the E6/F6 primer pair (Figure S5A). Other PCR
products are, however, predicted to be in frame, though still
disruptive of protein structure, including products in which
EWSR1 exon 7 (labels b, d, and e in Figure 5C) or FLI1 exon 5
are spliced to FLI1 exon 8 (label f in Figure 5C). The silencing
of other U2 snRNP components identified by the RNAi screen
mediated a similar decrease in the expression and mis-splicing
of EWS-FLI1 (Figures S5B and S5C). These findings suggest
that expression of full-length EWS-FLI1, expressed in ES cell
lines representing different fusion types, requires optimal activity
of the U2 snRNP.
To more fully understand the effect of inhibiting U2 snRNP
function on the splicing of EWS-FLI1, we turned to a pharmaco-
logical inhibitor of the SF3b spliceosome subunit, Pladienolide B
(PlaB) (Kotake et al., 2007; Yokoi et al., 2011). First, we assessed
the effects of PlaB on EWS-FLI1 expression by treating ES cells
with PlaB (1.25–10 nM, 6 hr) (Figures 5D and S5D). Using the E7/
F7 and E7/F9 primer pairs, we detected concentration-depen-
dent differences in EWS-FLI1 expression that phenocopied
those observed following SF3B1 silencing. To confirm that we
were detecting the same EWS-FLI1 transcript variants as
observed in SF3B1-silenced ES cells, we assessed the splicing
of EWS-FLI1 in ES cells treated with 5 nM PlaB (6 hr). Following
PlaB treatment, we observed the failure of TC32 cells to exclude
EWSR1 exon 8 when processing EWS-FLI1 (Figure S5E) and the
mis-splicing of EWS-FLI1 at the exons adjacent to the break-
point (Figures 5E and S5F). The consequence of PlaB treatment
on the splicing of EWS-FLI1was also evident whenwe examined
EWS-FLI1 protein, as at the two highest concentrations of PlaB
(24 hr), we detectedmultiple protein bands (Figures 5F and S5G).
In order to begin to characterize the variant protein products of
mis-spliced EWS-FLI1 transcripts, we immunoprecipitated(F) The fold enrichment for HNRNPH1-bound RNA oligomers determined by co
HNRNPH1 antibody and an IgG isotype control. Data are shown as themean ± SE
controls. n.s., not significant.
See also Figure S4.
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TC32 or SKNMC cell lysates and performed mass spectrometry
analysis. Under these conditions, we identified one unique
peptide present in PlaB-treated samples that was not present
in control samples (Figure 5G). Though this peptide differs by
only one amino acid (N) from a peptide observed in DMSO-
and PlaB-treated cells (D), we were intrigued that this is precisely
the sequence change predicted if either FLI1 exon 7 is excluded
or FLI1 exons 7 and 8 are excluded (Figure 5G). PCR analysis of
the splicing of FLI1 exons following PlaB treatment of ES cells (or
the silencing of SF3B1) detected transcripts in which FLI1 exon 7
is excluded (Figure 5H; Figure S5H), suggesting that mis-spliced
EWS-FLI1 transcripts may have the potential to express variant
EWS-FLI1 proteins, though further study will be required to
confirm this.
The Inhibition of SF3bReverses theExpression ofGenes
Activated by EWS-FLI1
Several studies have assessed the cytotoxic activity of PlaB on
cancer cells, reporting half-maximal inhibitory concentration
(IC50) values ranging between 0.5 and 8.5 nM (Kotake et al.,
2007; Sato et al., 2014; Yokoi et al., 2011). The PlaB IC50 values
for ES cells (at 48 hr) ranged between 1.5 and 2.5 nM; values
comparable with those determined for two non-fusion driven
prostate cancer cell lines, PC3 and LNCaP (Figure 6A). However,
we observed that the responses of ES cells to PlaB differed from
responses of the prostate cancer cell lines and the published re-
sponses of two other cancer cell lines, HeLa and DLD-1 (Kotake
et al., 2007; Yokoi et al., 2011). Specifically, the cytotoxic activity
of PlaB on non-ES cells plateaued without inducing a complete
reduction in cell viability, whereas ES cell lines exhibited near-
complete loss of cell viability (Figure S6A). A possible explana-
tion for this difference could be the disruption of EWS-FLI1
splicing mediated by PlaB and the resulting alteration in the
expression and activity of EWS-FLI1. To establish whether
PlaB treatment results in an alteration in EWS-FLI1 activity, we
profiled the transcriptome of ES cells treated with 5 nM PlaB
for 24 hr.
GSEA of the expression profiles of PlaB-treated ES cells
showed highly significant enrichment for reduced expression
of genes that are specifically disrupted in ES (normalized enrich-
ment score [NES], 1.85 to 2.43, FWER p < 0.001; and
NES, 2.11 to 2.22, FWER p < 0.001) (Figure 6B). There was
no enrichment for the increased expression of genes that are
downregulated in ES cells following PlaB treatment (Figure S6B).
Examination of specific genes that exhibited differential expres-
sion following PlaB treatment (Table S4) confirmed the
decreased expression of many EWS-FLI1-activated genes (Fig-
ure 6C). These data are consistent with PlaB treatment resulting
in the disruption of the activating function of EWS-FLI1 that
requires the binding of EWS-FLI1 multimers at GGAA microsat-
ellite sequences within cis-regulatory elements (Gangwal et al.,
2008; Riggi et al., 2014), but not the repressive function ofmparison of chemiluminiscent signals from the pull-down performed using a
M of three experiments. The p values are compared to no oligomer/no antibody
Figure 5. Depletion of SF3B1 Results in Mis-splicing of EWS-FLI1
(A) Immunoblot analysis of whole-cell lysates prepared from ES cells 48 hr post-siRNA transfection using antibodies against the proteins indicated.
(B) EWS-FLI1 expression (E7/F7 or E7/F9 primer pairs) following silencing of HNRNPH1 or SF3B1 in SKNMC cells. Data are expressed relative to siNeg-
transfected cells (mean ± SD, n = 3). Expression of RPL27 is shown as a control for assessing non-specific splicing effects. *p < 0.05; **p < 0.01; ***p < 0.001,
compared to siNeg.
(C) PCR analysis of the splicing of EWS-FLI1 using primers corresponding to EWSR1 exon 7 and FLI1 exon 8 and representative sequence chromatograms for the
PCR products indicated in each gel (a–f).
(legend continued on next page)
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EWS-FLI1 that, one recent study has proposed, is a result of the
displacement of the binding of other transcription factors at ca-
nonical ETS binding sites (Riggi et al., 2014). To further examine
the effect of disrupting spliceosome activity on the expression of
EWS-FLI1-activated genes, we conducted a qPCR analysis of
the expression of NR0B1, PRKCB, VRK1,GRK5, EZH2, FCGRT,
and NKX2.2 following PlaB treatment (four ES cell lines, 5 nM,
24 hr) (Figure 6D; Figure S6B) or the silencing of SF3B1 (TC32
and SKNMC cells, 48 hr) (Figure 6E). Overall, we observed a sub-
stantial decrease in the expression of each EWS-FLI1-activated
gene following either PlaB treatment or the silencing of SF3B1.
Importantly, with the exception of EZH2 (Figure S6C), we
observed no direct effect of PlaB treatment or the silencing of
SF3B1 on the splicing of these genes (data not shown). Extend-
ing our analysis to assessment of protein, we observed variable
decreases in the expression of NR0B1 following PlaB and
silencing of SF3B1, but we observed complete depletion of
PRKCB protein expression (Figure 6F). Consistent with this
observation using chromatin immunoprecipitation (ChIP) anal-
ysis, we observed a substantial reduction in the fold enrichment
of EWS-FLI1 binding at a reported enhancer sequence within the
PRKCB locus following PlaB treatment (Figure 6G). The fold
enrichment of EWS-FLI1 binding was also reduced at enhancer
sites within four other genes (VRK1, GRK5, EZH2, and FCGRT)
following PlaB treatment. Taken together, these data suggest
that the identification by RNAi screening of multiple members
of the U2 snRNP, as required for EWS-FLI1 activity, is because
the EWS-FLI1 transcript is particularly sensitive to the disruption
of spliceosome function. In particular, this altered splicing of the
EWS-FLI1 transcript is sufficient to disrupt the ability of the EWS-
FLI1 to activate the expression of EWS-FLI1 target genes,
including genes associated with ES tumorigenesis.
DISCUSSION
ES is dependent on the EWS-FLI1 transcription factor for cell
survival and maintenance of the malignant phenotype. Unfortu-
nately, EWS-FLI1 has proven to be a challenging drug target
(Grohar and Helman, 2013; Kovar, 2014). Therefore, the goal of
this study was to identify therapeutic vulnerabilities in EWS-
FLI1 activity that are more amenable to drug development. In or-
der to identify these vulnerabilities, we used a genome-wide
RNAi screen to identify genes that modulate EWS-FLI1 activity.
We subsequently linked lead candidate genes identified by the
screen to the biogenesis of EWS-FLI1 itself. We report that the
EWS-FLI1 transcript expressed in 85% of ES tumors is vulner-(D) Expression of EWS-FLI1 in TC32 cells treated with increasing concentrations
cells (mean ± SD, n = 3). *p < 0.05; **p < 0.01; ***p < 0.001 compared to V.
(E) PCR analysis of the splicing of EWS-FLI1 using primers corresponding to EWSR
PCR product indicated by *. TC32 cells were treated with 5 nM PlaB for 6 hr.
(F) Immunoblot analysis of whole-cell lysates prepared from TC32 cells treated
proteins indicated.
(G) Higher energy collisional dissociation (HCD) fragmentation spectra of peptide (
The protein band corresponding to EWS-FLI1 was excised and digested with tryp
Fusion mass spectrometer.
(H) PCR analysis of the splicing of EWS-FLI1 using a FLI1 exon 6 forward and a F
junction for the indicated product (asterisk).
See also Figure S5.
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ular, factors required to ensure the splicing of exons at, and
downstream of, the fusion breakpoint. We establish that splicing
at these exons is susceptible to mis-splicing when genes encod-
ing components of the U2 snRNP are silenced or spliceosome
activity is inhibited (Figure 7, upper panel). We also identified
that HNRNPH1 is required for the removal of EWSR1 exon 8
from the EWS-FLI1 transcript expressed in cells with a chromo-
some 22 breakpoint downstream of EWSR1 exon 8 (Figure 7,
lower panel). Disruption of the splicing of EWS-FLI1 alters the
expression of the EWS-FLI1 protein and reverses the expression
of a significant proportion of the genes EWS-FLI1 deregulates,
including many of the genes required for the survival of ES cells.
This study opens up a potential strategy for the treatment of ES
through disruption of the processing of the EWS-FLI1 fusion
transcript itself.
HNRNPH1 contains three repeats of the quasi-RRM domain
that binds to RNA at G triplet (GGGn) tracts typically positioned
in close proximity to 50 or 30 splice sites (ss) (Caputi and Zahler,
2001; Huelga et al., 2012; Xiao et al., 2009). HNRNPH1 can either
enhance or inhibit the use of an alternatively spliced exon, de-
pending on the length of the G tracts, the intronic versus exonic
position, and the strength of the 50 ss (Xiao et al., 2009).
HNRNPH1 and its binding sites in exon 8 of EWSR1 are intriguing
putative drug targets. No small molecule inhibitor of HNRNPH1
has been described, but a logical next step will be to screen
for such a compound or for an RNA-bindingmolecule that blocks
the interaction of HNRNPH1 with the EWS-FLI1 pre-mRNA.
Importantly, a molecule that blocks the excision of EWSR1
exon 8 from the EWS-FLI1 pre-mRNA could have the advantage
of sequence and structure specificity. This will not be applicable
in all cases of ES, but a recent study estimated that 35% of ES
tumors harbor a breakpoint that retains EWSR1 exon 8 (Berger
et al., 2013), and awhole-genome sequencing study of six ES tu-
mors showed that four harborEWSR1 intron 8 breakpoints (Brohl
et al., 2014).
In contrast to HNRNPH1, the requirement for SF3B1 activity is
breakpoint independent, with the inhibition of SF3B1 function re-
sulting in altered splicing of EWS-FLI1 fusion transcripts regard-
less of the position of the fusion breakpoint. The challenge of
SF3B1-directed therapies will be exploiting the vulnerability of
the EWS-FLI1 fusion transcript while minimizing general effects
on splicing. The importance of SF3B1 in tumorigenesis has
recently become appreciated with the identification of mutations
in SF3B1 (Scott and Rebel, 2013). These findings have stimu-
lated interest in the development of compound inhibitors of theof PlaB (1.25–10 nM, 6 hr). Data are expressed relative to 0.1% DMSO-treated
1 exon 7 and FLI1 exon 8 and representative sequence chromatograms for the
with increasing concentrations of PlaB for 24 hr using antibodies against the
[M+2H]2+-H2O,m/z 657.62) from SKMNC cells treated with 5 nMPlaB for 24 hr.
sin, and the resulting peptides were analyzed on a Thermo Scientific Orbitrap
L11 exon 9 reverse primer and representative sequences of the FLI1 exon 6/8
Figure 6. Inhibition of SF3b Function Reverses Expression of Genes Activated by EWS-FLI1
(A) The viability of ES (TC32, SKNMC, TC71, and RD-ES) and prostate cancer (PC3 and LNCaP) cell lines exposed to increasing concentrations of the
spliceosome inhibitor PlaB for 48 hr (mean ± SEM, n = 3) at each PlaB concentration normalized to vehicle (V, 0.1% DMSO). CI, confidence interval.
(B) GSEA of the transcriptome of PlaB-treated ES cells (5 nM, 24 hr) using a set of 751 genes upregulated in ES and a set of 100 genes activated by EWS-FLI1
(Riggi et al., 2014).
(C) Heatmap of the fold change (Log2) in the expression of EWS-FLI1-regulated genes (Kauer et al., 2009) and genes considered direct targets of EWS-FLI1 (Riggi
et al., 2014) following exposure of ES cells to PlaB (5 nM for 24 hr).
(D) Expression of genes activated by EWS-FLI1 in PlaB-treated (5 nM for 24 hr) TC32 or SKNMC cells. Data are expressed relative to DMSO-treated cells
(mean ± SD, n = 3). *p < 0.05; **p < 0.01; ***p < 0.001, compared to siNeg or V.
(legend continued on next page)
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Figure 7. The Altered Splicing of EWS-FLI1
Results in Disruption of Its Activity as an
Oncogenic Transcription Factor
Schematic illustrating the splicing of the EWS-FLI1
pre-mRNA by SF3B1 and HNRNPH1.spliceosome (Bonnal et al., 2012; Webb et al., 2013). In this
study, we showed that the effect of silencing of SF3B1 on the
splicing of EWS-FLI1 is phenocopied by a small molecule inhib-
itor of the spliceosome, PlaB. The toxicity of this compound pre-
cluded in vivo evaluation, but other splicing inhibitors are in
development (Eskens et al., 2013; Folco et al., 2011; Hong
et al., 2014). As these compounds become available, their eval-
uation in ES is warranted. An alternative approach will be to
consider other components of the spliceosome and other
RNA-processing proteins identified by RNAi screening as
required for EWS-FLI1 activity, as one or more of these may pro-
vide a more effective and less toxic target.
The aberrant splicing of EWS-FLI1 resulting from the inhibition
of spliceosome function also provided insight into the biology of
ES. The analysis of the downstream consequences of PlaB treat-
ment on ES cells clearly distinguished the two modes by which
EWS-FLI1 regulates gene expression. It could be that activated
targets of EWS-FLI1 are more vulnerable to a reduction in
expression of the full-length EWS-FLI1 oncoprotein because of(E) Expression of genes activated by EWS-FLI1 in SF3B1-silenced TC32 or SKNMC cells (48 hr). Data
(mean ± SD, n = 3). *p < 0.05; **p < 0.01; ***p < 0.001, compared to siNeg.
(F) Immunoblot analysis of whole-cell lysates prepared from ES cells treated with either 0.1% DMSO or 5 nm
cells using antibodies against the proteins indicated.
(G) ChIP analysis of DNA from TC32 cells (treated with 0.1%DMSO or 5 nM PlaB for 24 hr) using either a FLI1
precipitating DNA (PlaB compared to DMSO) was determined by qPCR for the indicated EWS-FLI1 bound G
PCR primers used are detailed in Supplemental Experimental Procedures (mean ± SEM, three independent e
each experiment).
See also Figure S6 and Tables S2 and S4.
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EWS-FLI1 to GGAA microsatellite se-
quences, or the variant EWS-FLI1 pro-
teins encoded by mis-spliced EWS-FLI1
transcripts could have different binding
effects at GGAA microsatellites than at
repressive ETS consensus sites. Further
analysis of the transcriptional activity of
variant proteins generated following the
mis-splicing of EWS-FLI1may give insight
into how the oncoprotein deregulates the
expression of specific genes. This study
also has implications for other tumor
types dependent upon the expression of
a fusion gene for cell survival. For
example, as for the EWSR1 exon 8 con-
taining EWS-FLI1 pre-mRNA, there is ev-
idence that the first NUT exon must be
spliced out to generate the in-frame
BRD4–NUT fusion observed in nuclear
protein in testis (NUT)-midline carci-
nomas harboring t(15;19) translocations(Thompson-Wicking et al., 2013). The application of a functional
genomic approach akin to that used in this study has the poten-
tial to identify proteins required for specific steps in the matura-
tion of other fusion transcripts and thereby provide new strate-
gies for the treatment of fusion-driven tumors.
EXPERIMENTAL PROCEDURES
RNAi Screen
The RNAi screen of EWS-FLI1 activity was conducted using a siRNA library
targeting 21,000 human genes, three siRNAs per gene, and TC32-NR0B1-
luc and TC32-CMV-luc reporter lines (Grohar et al., 2011). Parallel transfec-
tions were conducted in each cell line, and luciferase expression was assayed
48 hr later. The raw luciferase data for each screen were normalized
and Z score-MAD (median absolute deviation) transformed, and a seed-
adjusted Z was calculated for each siRNA (Buehler et al., 2012;
Marine et al., 2012). The difference between the Z for each siRNA in each
screen (Zdiff = ZNR0B1  ZCMV) was used to identify siRNAs that alter EWS-
FLI1 activity. The confirmatory screen was conducted under analogous assay
conditions using at least four siRNAs per gene. Cell viability was measured us-
ing the CellTiter-Glo Luminescent Cell Viability Assay (Promega).are expressed relative to siNeg-transfected cells
PlaB (24 hr) or siNeg or SF3B1-silenced (48 hr) ES
antibody or an IgG antibody. Fold enrichment of co-
GAA microsatellites; the regions targeted and the
xperiments, triplicate samples for each treatment in
Gene Expression Analysis
Gene expression was assayed by qRT-PCR using Fast SYBR Green Master
Mix and the StepOnePlus Real-Time PCR System (Applied Biosystems) or us-
ing Human HT-12 v4 BeadChip Illumina arrays (Illumina). A gene was consid-
ered differentially expressed if probes had an average log2 fold change of ±0.6
(1.5 fold change on a linear scale) and a q value (FDR) < 0.05. For analysis of
splicing, RNA was reverse transcribed using iScript Reverse Transcription
Supermix (Bio-Rad), and PCR products were amplified using Platinum PCR
SuperMix High Fidelity (Invitrogen). For sequencing, PCR products were
further amplified using T7-forward and T3-reverse tagged primers and,
following gel electrophoresis and extraction, were sequenced using an ABI
3130 XL Genetic Analyzer (Applied Biosystems).
RNA Pull-Down and Binding Assays
Cellswere irradiated andharvestedby scraping, and the cytoplasmic andnuclei
fractionswere separated (CelLyticNuCLEARExtractionKit, Sigma-Aldrich). The
protein-RNA complexes were immunopurifiedwith an anti-HNRNPH1 antibody
(A300-511A, Bethyl Laboratories) or a rabbit IgG (mock control, Molecular
Probes) immobilized on protein-A-coated Dynabeads (Novex). Crosslinked
RNAswere releasedusingproteinaseK (RocheLifeSciences), purified, reversed
transcribed, and amplified using primers spanning different regions of EWS-
FLI1. The enrichment ratio was calculated by comparison of the quantification
of normalized HNRNPH1 pull-down RNA to mock pull-down RNA.
For the RNA-binding assay, an IgG antibody-coated 96-well plate (Pierce)
was washed and then incubated with an anti-HNRNPH1 antibody or rabbit
IgG. Whole-cell lysate and biotin-labeled oligomer were combined and UV
crosslinked. Following washing to remove unbound oligomer, the protein-olig-
omer complex was added to each well of the antibody-coated plate, and the
plate was incubated for 1 hr. Unbound protein was removed by washing,
and the bound protein-oligomer complex was detected using Streptavidin-
HRP (horseradish peroxidase) (Pierce).
Immunoblotting, Mass Spectrometry, and ChIP Analysis
Immunoblotting was performed using standard procedures. For mass spec-
trometry, EWS-FLI1 protein was immunoprecipitated using a FLI1 antibody
(Abcam), and samples were separated in a Novex 4%–20% Tris-glycine pro-
tein gel at 140 V and subsequently Coomassie stained. Bands corresponding
to EWS-FLI1 were excised from the gel, and in-gel tryptic digestion was per-
formed. Experiments were performed on a Thermo Scientific Orbitrap Fusion
mass spectrometer. Peptides were identified using Proteome Discoverer, with
a minimum Xcorr score of 2.2. ChIP was carried out using a magnetic bead-
based kit (Millipore).
Computational and Statistical Analysis
The analysis of the EWS-FLI1-regulated genes used data reported by Hancock
andLessnick (2008)andKaueret al. (2009); seeTableS3.Gene-basedanalytical
tools were accessed through http://david.abcc.ncifcrf.gov/ or www.ingenuity.
com. Statistical analysis was conducted using a Student’s (heteroscedastic)
t test in Excel; p < 0.05 was considered significant. Concentration curves, IC50
values, and confidence intervals were generated using GraphPad Prism 6.
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